Clarity Pharmaceuticals Ltd

This phase 2 study tested a new radioactive imaging agent called 64Cu-SAR-BBN in 53 men with prostate cancer that had returned after treatment but was not visible on standard PSMA PET scans. The goal was to see if this agent could safely and accurately detect where the cancer had…